27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The science of large-scale brain networks offers a powerful paradigm for investigating cognitive and affective dysfunction in psychiatric and neurological disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The hippocampal formation has been implicated in a growing number of disorders, from Alzheimer's disease and cognitive ageing to schizophrenia and depression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Part of the inflammatory response in Alzheimer's disease (AD) is the upregulation of the inducible nitric oxide synthase (NOS2) resulting in increased NO production. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Human biomonitoring provides an efficient and cost-effective way to identify and quantify exposure to chemical substances, including those having deleterious eff ects on human organisms. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Essential polyunsaturated fatty acids (PUFAs) are critical nutritional lipids that must be obtained from the diet to sustain homeostasis. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Glutamate is an essential excitatory neurotransmitter regulating brain functions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
To realize the therapeutic potential of RNA drugs, efficient, tissue-specific and nonimmunogenic delivery technologies must be developed. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In Alzheimer's disease (AD), dementia severity correlates strongly with decreased synapse density in hippocampus and cortex. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Increasing evidence suggests that the accumulation of amyloid beta (Aβ) in synapses and synaptic mitochondria causes synaptic mitochondrial failure and synaptic degeneration in Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
For the past 40 years or so, oxidative stress has been increasingly recognized as a contributing factor in aging and in various forms of pathophysiology generally associated with aging. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of our study was to better understand the relationship between mitochondrial structural proteins, particularly dynamin-related protein 1 (Drp1) and amyloid beta (Aβ) in the progression of Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In 2009, nearly 66 million Americans (three in 10 U.S. households) reported at least one person providing unpaid care as a family caregiver. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Inhibition of phosphodiesterase 9 (PDE9) has been reported to enhance rodent cognitive function and may represent a potential novel approach to improving cognitive dysfunction in Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease is the most common cause of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The age-adjusted death rate decreased from 758.7 deaths per 100,000 population in 2008 to 741.0 deaths per 100,000 population in 2009. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Glutamate is the primary excitatory neurotransmitter in mammalian brain. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The brain is considered to be an immune privileged site, because the blood-brain barrier limits entry of blood borne cells and proteins into the central nervous system (CNS). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There are growing numbers of studies using machine learning approaches to characterize patterns of anatomical difference discernible from neuroimaging data. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Gait impairment is a prominent falls risk factor and a prevalent feature among older adults with cognitive impairment. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Besides cognitive decline, dementia is characterized by gait changes and increased fall risk, also in early stages of the disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Ts65Dn is a mouse model of Down syndrome: a syndrome that results from chromosome (Chr) 21 trisomy and is associated with congenital defects, cognitive impairment, and ultimately Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In addition to progressive dementia, Alzheimer's disease (AD) is characterized by increased incidence of seizure activity. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We here report on the synthesis, optimization, and biological characterization of leucettines, a family of kinase inhibitors derived from the marine sponge leucettamine B. Stepwise synthesis of analogues starting from the natural structure, guided by activity testing on eight purified kinases, led to highly potent inhibitors of CLKs and DYRKs, two families of kinases involved in alternative pre-mRNA splicing and Alzheimer's disease/Down syndrome. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Microinfarcts are common, and persons with multiple cortical microinfarcts have higher odds of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Brain extraction is an important step in the analysis of brain images. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →